Molecular interactions in interleukin and toll-like receptor signaling pathways

Current Pharmaceutical Design

Volumn 20, Issue 8, 2014, Pages 1244-1258

  Snyder, Greg A ^a   Sundberg, Eric J ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Innate immunity; Interleukin receptors; NF B; Peptides; Peptidomimetics; TIR domain; Toll like receptors

Indexed keywords

BACTERIAL PROTEIN; CYTOKINE; INTERLEUKIN 1 RECEPTOR; MYELOID DIFFERENTIATION FACTOR 88; PEPTIDOMIMETIC AGENT; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 6; VEGETABLE PROTEIN; VPR PROTEIN; MOLECULAR LIBRARY; PEPTIDE FRAGMENT;

ARTICLE; INNATE IMMUNITY; MOLECULAR SIZE; PARACOCCUS DENITRIFICANS; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR LIBRARY; MUTATION; PHARMACOLOGY; PROTEIN FOLDING; PROTEIN TERTIARY STRUCTURE;

DRUG DESIGN; HUMANS; IMMUNITY, INNATE; MUTATION; PEPTIDE FRAGMENTS; PEPTIDOMIMETICS; PROTEIN FOLDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, INTERLEUKIN-1; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; TOLL-LIKE RECEPTORS;

EID: 84903690421     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990069     Document Type: Article

References (199)

1. Rao ST, Rossmann MG. Comparison of super-secondary structures in proteins. J Mol Biol 1973; 76: 241-56.
2. Janeway CA, Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harbor Symposia on Quantitative Biology 1989; 54 Pt 1: 1-13.
3. Janeway CA, Jr., Medzhitov R. Innate immune recognition. Ann Rev Immunol 2002; 20: 197-216.
4. Gay NJ, Keith FJ. Drosophila Toll and IL-1 receptor. Nature 1991; 351: 355-6.
5. Medzhitov R, Preston-Hurlburt P, Janeway CA, Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388: 394-7.
6. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996; 86: 973-83.
7. Lord KA, Hoffman-Liebermann B, Liebermann DA. Nucleotide sequence and expression of a cDNA encoding MyD88, a novel myeloid differentiation primary response gene induced by IL6. Oncogene 1990; 5: 1095-7.
8. Fitzgerald KA, Palsson-McDermott EM, Bowie AG, et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 2001; 413: 78-83.
9. Horng T, Barton GM, Medzhitov R. TIRAP: an adapter molecule in the Toll signaling pathway. Nature Immunol 2001; 2: 835-41.
10. Yamamoto M, Sato S, Mori K, et al. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol 2002; 169: 6668-72.
11. Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nature Immunol 2003; 4: 161-7.
12. Oshiumi H, Sasai M, Shida K, Fujita T, Matsumoto M, Seya T. TIR-containing adapter molecule (TICAM)-2, a bridging adapter recruiting to toll-like receptor 4 TICAM-1 that induces interferonbeta. J Biological Chem 2003; 278: 49751-62.
13. Fitzgerald KA, Rowe DC, Barnes BJ, et al. LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med 2003; 198: 1043-55.
14. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007; 7: 353-64.
15. Burns K, Martinon F, Esslinger C, et al. MyD88, an adapter protein involved in interleukin-1 signaling. J Biol Chem 1998; 273: 12203-9.
16. Akira S, Takeda K. Toll-like receptor signalling. Nature reviews. Immunology 2004; 4: 499-511.
17. Lee MS, Kim YJ. Signaling pathways downstream of patternrecognition receptors and their cross talk. Ann Rev Biochem 2007; 76: 447-80.
18. Jin MS, Lee JO. Structures of the toll-like receptor family and its ligand complexes. Immunity 2008; 29: 182-91.
19. Huang H, Chang EJ, Lee Y, Kim JS, Kang SS, Kim HH. A genome-wide microarray analysis reveals anti-inflammatory target genes of paeonol in macrophages. Inflammation research: official J Eur Histamine Res Society... [et al.] 2008; 57: 189-98.
20. Kang JY, Lee JO. Structural biology of the Toll-like receptor family. Ann Rev Biochem 2011; 80: 917-41.
21. Ve T, Gay NJ, Mansell A, Kobe B, Kellie S. Adaptors in Toll-like receptor signalling and their potential as therapeutic targets. Curr Drug Targets 2012.
22. Rast JP, Smith LC, Loza-Coll M, Hibino T, Litman GW. Genomic insights into the immune system of the sea urchin. Science 2006; 314: 952-6.
23. Hibino T, Loza-Coll M, Messier C, et al. The immune gene repertoire encoded in the purple sea urchin genome. Developmental Biol 2006; 300: 349-65.
24. Roach JC, Glusman G, Rowen L, et al. The evolution of vertebrate Toll-like receptors. Proc Natl Acad Sci USA 2005; 102: 9577-82.
25. Buckley KM, Rast JP. Dynamic evolution of toll-like receptor multigene families in echinoderms. Frontiers Immunol 2012; 3: 136.
26. Walk A, Callahan J, Srisawangvong P, et al. Lipopolysaccharide enhances bactericidal activity in Dictyostelium discoideum cells. Developmental and comparative immunology 2011; 35: 850-6.
27. Casanova JL, Abel L, Quintana-Murci L. Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Ann Rev Immunol 2011; 29: 447-91.
28. Kenny EF, O'Neill LA. Signalling adaptors used by Toll-like receptors: an update. Cytokine 2008; 43: 342-9.
29. Brikos C, O'Neill LA. Signalling of toll-like receptors. Handbook of experimental Pharmacol 2008: 21-50.
30. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Ann Rev Immunol 2009; 27: 519-50.
31. Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nature Rev Immunology 2005; 5: 629-40.
32. Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol 2010; 10: 89-102.
33. Zhang Q, Zmasek CM, Cai X, Godzik A. TIR domain-containing adaptor SARM is a late addition to the ongoing microbe-host dialog. Developmental Comparative Immunol 2011; 35: 461-8.
34. Jenkins KA, Mansell A. TIR-containing adaptors in Toll-like receptor signalling. Cytokine 2010; 49: 237-44.
35. Cirl C, Miethke T. Microbial Toll/interleukin 1 receptor proteins: a new class of virulence factors. International J medical microbiology: IJMM 2010; 300: 396-401.
36. Boraschi D, Lucchesi D, Hainzl S, et al. IL-37: a new antiinflammatory cytokine of the IL-1 family. European Cytokine Network 2011; 22: 127-47.
37. Thomas C, Bazan JF, Garcia KC. Structure of the activating IL-1 receptor signaling complex. Nature structural & molecular biology 2012; 19: 455-7.
38. Brändén C-I, Tooze J. Introduction to protein structure. Garland Pub.: New York, NY 2009.
39. Garlanda C, Riva F, Polentarutti N, et al. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci US A 2004; 101: 3522-6.
40. Wald D, Qin J, Zhao Z, et al. SIGIRR, a negative regulator of Tolllike receptor-interleukin 1 receptor signaling. Nature Immunol 2003; 4: 920-7.
41. Lang D, Knop J, Wesche H, et al. The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness. J Immunol 1998; 161: 6871-7.
42. Dinarello C, Arend W, Sims J, et al. IL-1 family nomenclature. Nature Immunol 2010; 11: 973.
43. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunological reviews 2008; 223: 20-38.
44. Barksby HE, Lea SR, Preshaw PM, Taylor JJ. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clinical and experimental Immunol 2007; 149: 217-25.
45. Wang D, Zhang S, Li L, Liu X, Mei K, Wang X. Structural insights into the assembly and activation of IL-1beta with its receptors. Nature Immunol 2010; 11: 905-11.
46. Lingel A, Weiss TM, Niebuhr M, et al. Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes. Structure 2009; 17: 1398-410.
47. Lingel A, Fairbrother WJ. NMR assignments of the human cytokine interleukin-33. Biomolecular NMR assignments 2009; 3: 223-5.
48. Connolly DJ, O'Neill LA. New developments in Toll-like receptor targeted therapeutics. Current opinion in pharmacology 2012; 12: 510-8.
49. Khan JA, Brint EK, O'Neill LA, Tong L. Crystal structure of the Toll/interleukin-1 receptor domain of human IL-1RAPL. J Biological Chem 2004; 279: 31664-70.
50. Barton GM, Kagan JC. A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nature rev Immunol 2009; 9: 535-42.
51. Botos I, Segal DM, Davies DR. The structural biology of Toll-like receptors. Structure 2011; 19: 447-59.
52. Kagan JC, Su T, Horng T, Chow A, Akira S, Medzhitov R. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nature Immunol 2008; 9: 361-8.
53. Buwitt-Beckmann U, Heine H, Wiesmuller KH, Jung G, Brock R, Akira S, Ulmer AJ. Toll-like receptor 6-independent signaling by diacylated lipopeptides. European J Immunol 2005; 35: 282-9.
54. Kang JY, Nan X, Jin MS, et al. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 2009; 31: 873-84.
55. Zhou K, Kanai R, Lee P, Wang HW, Modis Y. Toll-like receptor 5 forms asymmetric dimers in the absence of flagellin. J structural Biol 2012; 177: 402-9.
56. Latz E, Verma A, Visintin A, et al. Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nature Immunol 2007; 8: 772-9.
57. Bell JK, Botos I, Hall PR, et al. The molecular structure of the Toll-like receptor 3 ligand-binding domain. Proc Natl Acad Sci US A 2005; 102: 10976-80.
58. Choe J, Kelker MS, Wilson IA. Crystal structure of human toll-like receptor 3 (TLR3) ectodomain. Science 2005; 309: 581-5.
59. Liu L, Botos I, Wang Y, et al. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 2008; 320: 379-81.
60. Jin MS, Kim SE, Heo JY, et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 2007; 130: 1071-82.
61. Kim HM, Park BS, Kim JI, et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 2007; 130: 906-17.
62. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009; 458: 1191-5.
63. Ohto U, Fukase K, Miyake K, Satow Y. Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science 2007; 316: 1632-4.
64. Leonard JN, Ghirlando R, Askins J, et al. The TLR3 signaling complex forms by cooperative receptor dimerization. Proc Natl Acad Sci USA 2008; 105: 258-63.
65. Botos I, Liu L, Wang Y, Segal DM, Davies DR. The toll-like receptor 3:dsRNA signaling complex. Biochimica et Biophysica acta 2009; 1789: 667-74.
66. Toshchakov VY, Szmacinski H, Couture LA, Lakowicz JR, Vogel SN. Targeting TLR4 signaling by TLR4 Toll/IL-1 receptor domain-derived decoy peptides: identification of the TLR4 Toll/IL-1 receptor domain dimerization interface. J Immunol 2011; 186: 4819-27.
67. Barton GM, Kagan JC, Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nature Immunol 2006; 7: 49-56.
68. Nishiya T, Kajita E, Miwa S, Defranco AL. TLR3 and TLR7 are targeted to the same intracellular compartments by distinct regulatory elements. J Biological Chem 2005; 280: 37107-17.
69. Barbalat R, Ewald SE, Mouchess ML, Barton GM. Nucleic acid recognition by the innate immune system. Ann Rev Immunol 2011; 29: 185-214.
70. Qin J, Qian Y, Yao J, Grace C, Li X. SIGIRR inhibits interleukin-1 receptor-and toll-like receptor 4-mediated signaling through different mechanisms. J Biological Chem 2005; 280: 25233-41.
71. Wang X, Lupardus P, Laporte SL, Garcia KC. Structural biology of shared cytokine receptors. Ann Rev Immunol 2009; 27: 29-60.
72. Thomassen E, Renshaw BR, Sims JE. Identification and characterization of SIGIRR, a molecule representing a novel subtype of the IL-1R superfamily. Cytokine 1999; 11: 389-99.
73. Garlanda C, Anders HJ, Mantovani A. TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization. Trends in Immunol 2009; 30: 439-46.
74. Boraschi D, Tagliabue A. The interleukin-1 receptor family. Vitamins and hormones 2006; 74: 229-54.
75. Brint EK, Xu D, Liu H, Dunne A, McKenzie AN, O'Neill LA, Liew FY. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nature Immunol 2004; 5: 373-9.
76. Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS letters 1989; 258: 301-4.
77. Bergers G, Reikerstorfer A, Braselmann S, Graninger P, Busslinger M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membranebound proteins related to the IL-1 receptor. EMBO Journal 1994; 13: 1176-88.
78. Klemenz R, Hoffmann S, Werenskiold AK. Serum-and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen. Proc Natl Acad Sci USA 1989; 86: 5708-12.
79. Lohning M, Stroehmann A, Coyle AJ, Grogan JL, Lin S, Gutierrez-Ramos JC, Levinson D, Radbruch A, Kamradt T. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl AcadSci USA 1998; 95: 6930-5.
80. Trajkovic V, Sweet MJ, Xu D. T1/ST2--an IL-1 receptor-like modulator of immune responses. Cytokine & growth factor Rev 2004; 15: 87-95.
81. Coyle AJ, Lloyd C, Tian J, et al. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J experimental Med 1999; 190: 895-902.
82. Xu D, Chan WL, Leung BP, et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 1998; 187: 787-94.
83. Dinarello CA. An IL-1 family member requires caspase-1 processing and signals through the ST2 receptor. Immunity 2005; 23: 461-2.
84. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23: 479-90.
85. Basith S, Manavalan B, Govindaraj RG, Choi S. In silico approach to inhibition of signaling pathways of Toll-like receptors 2 and 4 by ST2L. PloS one 2011; 6: e23989.
86. Meijer AH, Gabby Krens SF, Medina Rodriguez IA, et al. Expression analysis of the Toll-like receptor and TIR domain adaptor families of zebrafish. Mol Immunol 2004; 40: 773-83.
87. Couillault C, Pujol N, Reboul J, et al. TLR-independent control of innate immunity in Caenorhabditis elegans by the TIR domain adaptor protein TIR-1, an ortholog of human SARM. Nature Immunol 2004; 5: 488-94.
88. Mink M, Fogelgren B, Olszewski K, Maroy P, Csiszar K. A novel human gene (SARM) at chromosome 17q11 encodes a protein with a SAM motif and structural similarity to Armadillo/beta-catenin that is conserved in mouse, Drosophila, and Caenorhabditis elegans. Genomics 2001; 74: 234-44.
89. Carty M, Goodbody R, Schroder M, Stack J, Moynagh PN, Bowie AG. The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nature Immunol 2006; 7: 1074-81.
90. Hochrein H, Schlatter B, O'Keeffe M, et al. Herpes simplex virus type-1 induces IFN-alpha production via Toll-like receptor 9-dependent and-independent pathways. Proc Natl Acad Sci USA 2004; 101: 11416-21.
91. Jung A, Kato H, Kumagai Y, et al. Lymphocytoid choriomeningitis virus activates plasmacytoid dendritic cells and induces a cytotoxic T-cell response via MyD88. J Virol 2008; 82: 196-206.
92. Hokeness-Antonelli KL, Crane MJ, Dragoi AM, Chu WM, Salazar-Mather TP. IFN-alphabeta-mediated inflammatory responses and antiviral defense in liver is TLR9-independent but MyD88-dependent during murine cytomegalovirus infection. J Immunol 2007; 179: 6176-83.
93. Kim T, Pazhoor S, Bao M, et al. Aspartate-glutamate-alaninehistidine box motif (DEAH)/RNA helicase A helicases sense microbial DNA in human plasmacytoid dendritic cells. Proc Natl Acad Sci USA 2010; 107: 15181-6.
94. Ryan KA, Smith MF, Jr., Sanders MK, Ernst PB. Reactive oxygen and nitrogen species differentially regulate Toll-like receptor 4-mediated activation of NF-kappa B and interleukin-8 expression. Infection Immunity 2004; 72: 2123-30.
95. Suliman HB, Welty-Wolf KE, Carraway MS, Schwartz DA, Hollingsworth JW, Piantadosi CA. Toll-like receptor 4 mediates mitochondrial DNA damage and biogenic responses after heatinactivated E. coli. FASEB journal: official Publication Federation Am Soc Exp Biol 2005; 19: 1531-3.
96. Ohnishi H, Tochio H, Kato Z, et al. Structural basis for the multiple interactions of the MyD88 TIR domain in TLR4 signaling. Proc Natl Acad Sci USA 2009; 106: 10260-5.
97. Xu Y, Tao X, Shen B, et al. Structural basis for signal transduction by the Toll/interleukin-1 receptor domains. Nature 2000; 408: 111-5.
98. Tao X, Xu Y, Zheng Y, Beg AA, Tong L. An extensively associated dimer in the structure of the C713S mutant of the TIR domain of human TLR2. Biochem Biophys Res Communications 2002; 299: 216-21.
99. Nyman T, Stenmark P, Flodin S, Johansson I, Hammarstrom M, Nordlund P. The crystal structure of the human toll-like receptor 10 cytoplasmic domain reveals a putative signaling dimer. J Biological Chem 2008; 283: 11861-5.
100. Bernoux M, Ve T, Williams S, et al. Structural and functional analysis of a plant resistance protein TIR domain reveals interfaces for self-association, signaling, and autoregulation. Cell Host Microbe 2011; 9: 200-11.
101. Chan SL, Low LY, Hsu S, et al. Molecular mimicry in innate immunity: crystal structure of a bacterial TIR domain. J Biological Chem 2009; 284: 21386-92.
102. Chan SL, Mukasa T, Santelli E, Low LY, Pascual J. The crystal structure of a TIR domain from Arabidopsis thaliana reveals a conserved helical region unique to plants. Protein science: a publication Protein Soc 2010; 19: 155-61.
103. Valkov E, Stamp A, Dimaio F, et al. Crystal structure of Toll-like receptor adaptor MAL/TIRAP reveals the molecular basis for signal transduction and disease protection. Proc Natl Acad Sci USA 2011; 108: 14879-84.
104. Lin Z, Lu J, Zhou W, Shen Y. Structural insights into TIR domain specificity of the bridging adaptor Mal in TLR4 signaling. PloS one 2012; 7: e34202.
105. Motshwene PG, Moncrieffe MC, Grossmann JG, et al. An oligomeric signaling platform formed by the Toll-like receptor signal transducers MyD88 and IRAK-4. J Biological Chem 2009; 284: 25404-11.
106. Lin SC, Lo YC, Wu H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature 2010; 465: 885-90.
107. Khan JA, Brint EK, O'Neill LA, Tong L. Crystal structure of the Toll/interleukin-1 receptor domain of human IL-1RAPL. J Biol Chem 2004; 279: 31664-70.
108. Mitcham JL, Parnet P, Bonnert TP, et al. T1/ST2 signaling establishes it as a member of an expanding interleukin-1 receptor family. J Biological Chem 1996; 271: 5777-83.
109. Rhee SH, Hwang D. Murine TOLL-like receptor 4 confers lipopolysaccharide responsiveness as determined by activation of NF kappa B and expression of the inducible cyclooxygenase. J Biological Chem 2000; 275: 34035-40.
110. Malley R, Henneke P, Morse SC, et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci USA 2003; 100: 1966-71.
111. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282: 2085-8.
112. Schneider DS, Hudson KL, Lin TY, Anderson KV. Dominant and recessive mutations define functional domains of Toll, a transmembrane protein required for dorsal-ventral polarity in the Drosophila embryo. Genes Development 1991; 5: 797-807.
113. Slack JL, Schooley K, Bonnert TP, et al. Identification of two major sites in the type I interleukin-1 receptor cytoplasmic region responsible for coupling to pro-inflammatory signaling pathways. J Biological Chem 2000; 275: 4670-8.
114. Nunez Miguel R, Wong J, Westoll JF, et al. A dimer of the Tolllike receptor 4 cytoplasmic domain provides a specific scaffold for the recruitment of signalling adaptor proteins. PloS one 2007; 2: e788.
115. Bovijn C, Ulrichts P, De Smet AS, et al. Identification of interaction sites for dimerization and adapter recruitment in Toll/interleukin-1 receptor (TIR) domain of Toll-like receptor 4. J Biological Chem 2012; 287: 4088-98.
116. Nada M, Ohnishi H, Tochio H, et al. Molecular analysis of the binding mode of Toll/interleukin-1 receptor (TIR) domain proteins during TLR2 signaling. Molecular Immunol 2012; 52: 108-16.
117. von Bernuth H, Picard C, Jin Z, et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 2008; 321: 691-6.
118. Takeuchi O, Hoshino K, Akira S. Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol 2000; 165: 5392-6.
119. Togbe D, Aurore G, Noulin N, et al. Nonredundant roles of TIRAP and MyD88 in airway response to endotoxin, independent of TRIF, IL-1 and IL-18 pathways. Laboratory investigation; a J Tech Methods Pathol 2006; 86: 1126-35.
120. Scanga CA, Aliberti J, Jankovic D, et al. Cutting edge: MyD88 is required for resistance to Toxoplasma gondii infection and regulates parasite-induced IL-12 production by dendritic cells. J Immunol 2002; 168: 5997-6001.
121. Muraille E, De Trez C, Brait M, De Baetselier P, Leo O, Carlier Y. Genetically resistant mice lacking MyD88-adapter protein display a high susceptibility to Leishmania major infection associated with a polarized Th2 response. J Immunol 2003; 170: 4237-41.
122. Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470: 115-9.
123. Gautam JK, Ashish, Comeau LD, Krueger JK, Smith MF, Jr. Structural and functional evidence for the role of the TLR2 DD loop in TLR1/TLR2 heterodimerization and signaling. J Biological Chem 2006; 281: 30132-42.
124. Toshchakov VU, Basu S, Fenton MJ, Vogel SN. Differential involvement of BB loops of toll-IL-1 resistance (TIR) domaincontaining adapter proteins in TLR4-versus TLR2-mediated signal transduction. J Immunol 2005; 175: 494-500.
125. George J, Kubarenko AV, Rautanen A, et al. MyD88 adaptor-like D96N is a naturally occurring loss-of-function variant of TIRAP. J Immunol 2010; 184: 3025-32.
126. Khor CC, Chapman SJ, Vannberg FO, et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nature genetics 2007; 39: 523-8.
127. Castiblanco J, Varela DC, Castano-Rodriguez N, Rojas-Villarraga A, Hincapie ME, Anaya JM. TIRAP (MAL) S180L polymorphism is a common protective factor against developing tuberculosis and systemic lupus erythematosus. Infection, genetics and evolution: J molecular epidemiology and evolutionary genetics in infectious diseases 2008; 8: 541-4.
128. Jeyaseelan S, Young SK, Yamamoto M, et al. Toll/IL-1R domaincontaining adaptor protein (TIRAP) is a critical mediator of antibacterial defense in the lung against Klebsiella pneumoniae but not Pseudomonas aeruginosa. J Immunol 2006; 177: 538-47.
129. Jerke S, Srinivasan A, McSorley SJ. Expression of Toll/IL-1R domain-containing adaptor protein (TIRAP) is detrimental to primary clearance of Salmonella and is not required for the generation of protective immunity. Immunol letters 2008; 116: 64-71.
130. Tanimura N, Saitoh S, Matsumoto F, Akashi-Takamura S, Miyake K. Roles for LPS-dependent interaction and relocation of TLR4 and TRAM in TRIF-signaling. Biochem Biophys Res Comm 2008; 368: 94-9.
131. Jiang Z, Georgel P, Li C, et al. Details of Toll-like receptor:adapter interaction revealed by germ-line mutagenesis. Proc Natl Acad Sci USA 2006; 103: 10961-6.
132. Yamamoto M, Sato S, Hemmi H, et al. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 2002; 420: 324-9.
133. Horng T, Barton GM, Flavell RA, Medzhitov R. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 2002; 420: 329-33.
134. Gray P, Dunne A, Brikos C, Jefferies CA, Doyle SL, O'Neill LA. MyD88 adapter-like (Mal) is phosphorylated by Bruton's tyrosine kinase during TLR2 and TLR4 signal transduction. J Biological Chem 2006; 281: 10489-95.
135. Piao W, Song C, Chen H, Wahl LM, Fitzgerald KA, O'Neill LA, Medvedev AE. Tyrosine phosphorylation of MyD88 adapter-like (Mal) is critical for signal transduction and blocked in endotoxin tolerance. J Biological Chem 2008; 283: 3109-19.
136. Verstak B, Nagpal K, Bottomley SP, Golenbock DT, Hertzog PJ, Mansell A. MyD88 adapter-like (Mal)/TIRAP interaction with TRAF6 is critical for TLR2-and TLR4-mediated NF-kappaB proinflammatory responses. J Biological Chem 2009; 284: 24192-203.
137. Mansell A, Brint E, Gould JA, O'Neill LA, Hertzog PJ. Mal interacts with tumor necrosis factor receptor-associated factor (TRAF)-6 to mediate NF-kappaB activation by toll-like receptor (TLR)-2 and TLR4. J Biological Chem 2004; 279: 37227-30.
138. van Lint AL, Murawski MR, Goodbody RE,. Herpes simplex virus immediate-early ICP0 protein inhibits Toll-like receptor 2-dependent inflammatory responses and NF-kappaB signaling. J Virol 2010; 84: 10802-11.
139. Ulrichts P, Bovijn C, Lievens S, Beyaert R, Tavernier J, Peelman F. Caspase-1 targets the TLR adaptor Mal at a crucial TIR-domain interaction site. J cell science 2010; 123: 256-65.
140. Rauscher JF, Cox CA, Yi T, et al. Synthesis, structure, magnetism, and high temperature thermoelectric properties of Ge doped Yb14MnSb11. Dalton transactions 2010; 39: 1055-62.
141. Condron CL, Kauzlarich SM, Ikeda T, Snyder GJ, Haarmann F, Jeglic P. Synthesis, structure, and high-temperature thermoelectric properties of boron-doped Ba8Al14Si31 clathrate I phases. Inorganic chemistry 2008; 47: 8204-12.
142. Couture LA, Piao W, Ru LW, Vogel SN, Toshchakov VY. Targeting Toll-like Receptor (TLR) Signaling by Toll/Interleukin-1 Receptor (TIR) Domain-containing Adapter Protein/MyD88 Adapter-like (TIRAP/Mal)-derived Decoy Peptides. J Biological Chem 2012; 287: 24641-8.
143. Cirl C, Wieser A, Yadav M, et al. Subversion of Toll-like receptor signaling by a unique family of bacterial Toll/interleukin-1 receptor domain-containing proteins. Nature Med 2008; 14: 399-406.
144. Low LY, Mukasa T, Reed JC, Pascual J. Characterization of a TIRlike protein from Paracoccus denitrificans. Biochemical and biophysical research communications 2007; 356: 481-6.
145. Chen G, Zhuchenko O, Kuspa A. Immune-like phagocyte activity in the social amoeba. Science 2007; 317: 678-81.
146. Wu B, Huan T, Gong J, Zhou P, Bai Z. Domain combination of the vertebrate-like TLR gene family: implications for their origin and evolution. J genetics 2011; 90: 401-8.
147. Rana RR, Simpson P, Zhang M. Yersinia pestis TIR-domain protein forms dimers that interact with the human adaptor protein MyD88. Microbial Pathogenesis 2011; 51: 89-95.
148. Salcedo R, Worschech A, Cardone M, et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med 2010; 207: 1625-36.
149. Radhakrishnan GK, Yu Q, Harms JS, Splitter GA. Brucella TIR Domain-containing Protein Mimics Properties of the Toll-like Receptor Adaptor Protein TIRAP. J Biological Chem 2009; 284: 9892-8.
150. Holden MT, Feil EJ, Lindsay JA, et al. Complete genomes of two clinical Staphylococcus aureus strains: evidence for the rapid evolution of virulence and drug resistance. Proc Natl Acad Sci USA 2004; 101: 9786-91.
151. Newman RM, Salunkhe P, Godzik A, Reed JC. Identification and characterization of a novel bacterial virulence factor that shares homology with mammalian Toll/interleukin-1 receptor family proteins. Infection Immunity 2006; 74: 594-601.
152. Bowie A, Kiss-Toth E, Symons JA, Smith GL, Dower SK, O'Neill LA. A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proce Natl Acad Sc USA 2000; 97: 10162-7.
153. Xiao TS. Subversion of innate immune signaling through molecular mimicry. J clinical Immunol 2010; 30: 638-42.
154. Sengupta D, Koblansky A, Gaines J, et al. Subversion of innate immune responses by Brucella through the targeted degradation of the TLR signaling adapter, MAL. J Immunol 2010; 184: 956-64.
155. Schubert S, Norenberg D, Clermont O, et al. Prevalence and phylogenetic history of the TcpC virulence determinant in Escherichia coli. International J Med microbiology: IJMM 2010; 300: 429-34.
156. Yadav M, Zhang J, Fischer H, et al. Inhibition of TIR domain signaling by TcpC: MyD88-dependent and independent effects on Escherichia coli virulence. PLoS pathogens 2010; 6: e1001120.
157. Radhakrishnan GK, Splitter GA. Biochemical and functional analysis of TIR domain containing protein from Brucella melitensis. Biochem Biophys Res Comm 2010; 397: 59-63.
158. Chaudhary A, Ganguly K, Cabantous S, et al. The Brucella TIRlike protein TcpB interacts with the death domain of MyD88. Biochemical Biophys Res Comm 2012; 417: 299-304.
159. Radhakrishnan GK, Harms JS, Splitter GA. Modulation of microtubule dynamics by a TIR domain protein from the intracellular pathogen Brucella melitensis. Biochemical J 2011; 439: 79-83.
160. Chan SL, Low LY, Hsu S, et al. Molecular mimicry in innate immunity: crystal structure of a bacterial TIR domain. J Biol Chem 2009; 284: 21386-92.
161. Bowie AG, Haga IR. The role of Toll-like receptors in the host response to viruses. Mol Immunol 2005; 42: 859-67.
162. Stack J, Haga IR, Schroder M, et al. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J Exp Med 2005; 201: 1007-18.
163. Gonzalez JM, Esteban M. A poxvirus Bcl-2-like gene family involved in regulation of host immune response: sequence similarity and evolutionary history. Virol J 2010; 7: 59.
164. Graham SC, Bahar MW, Cooray S, et al. Vaccinia virus proteins A52 and B14 Share a Bcl-2-like fold but have evolved to inhibit NF-kappaB rather than apoptosis. PLoS pathogens 2008; 4: e1000128.
165. Oda S, Franklin E, Khan AR. Poxvirus A46 protein binds to TIR domain-containing Mal/TIRAP via an alpha-helical sub-domain. Molecular Immunol 2011; 48: 2144-50.
166. Lysakova-Devine T, Keogh B, Harrington B, et al. Viral inhibitory peptide of TLR4, a peptide derived from vaccinia protein A46, specifically inhibits TLR4 by directly targeting MyD88 adaptorlike and TRIF-related adaptor molecule. J Immunol 2010; 185: 4261-71.
167. Chisholm ST, Coaker G, Day B, Staskawicz BJ. Host-microbe interactions: shaping the evolution of the plant immune response. Cell 2006; 124: 803-14.
168. Jones JD, Dangl JL. The plant immune system. Nature 2006; 444: 323-9.
169. Dodds PN, Rathjen JP. Plant immunity: towards an integrated view of plant-pathogen interactions. Nature reviews. Genetics 2010; 11: 539-48.
170. Ve T, Williams S, Valkov E, Ellis JG, Dodds PN, Kobe B. Crystallization, X-ray diffraction analysis and preliminary structure determination of the TIR domain from the flax resistance protein L6. Acta crystallographica. Section F, Structural Biol Crystallization Comm 2011; 67: 237-40.
171. Picard C, Casanova JL, Puel A. Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IkappaBalpha deficiency. Clinical Microbiol Rev 2011; 24: 490-7.
172. Bousfiha A, Picard C, Boisson-Dupuis S, et al. Primary immunodeficiencies of protective immunity to primary infections. Clin Immunol 2010; 135: 204-9.
173. Toshchakov VY, Vogel SN. Cell-penetrating TIR BB loop decoy peptides a novel class of TLR signaling inhibitors and a tool to study topology of TIR-TIR interactions. Expert Opinion Biological Therap 2007; 7: 1035-50.
174. Loiarro M, Ruggiero V, Sette C. Targeting TLR/IL-1R signalling in human diseases. Mediators Inflammation 2010; 2010: 674363.
175. Bartfai T, Behrens MM, Gaidarova S, Pemberton J, Shivanyuk A, Rebek J, Jr. A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses. Proce Natl Acad Sc USA 2003; 100: 7971-6.
176. Loiarro M, Sette C, Gallo G, et al. Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependent activation of NF-{kappa}B. J Biological Chem 2005; 280: 15809-14.
177. Loiarro M, Capolunghi F, Fanto N, et al. Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J leukocyte Biol 2007; 82: 801-10.
178. Fanto N, Gallo G, Ciacci A, et al. Design, synthesis, and in vitro activity of peptidomimetic inhibitors of myeloid differentiation factor 88. J Med Chem 2008; 51: 1189-202.
179. Toshchakov VY, Fenton MJ, Vogel SN. Cutting Edge: Differential inhibition of TLR signaling pathways by cell-permeable peptides representing BB loops of TLRs. J Immunol 2007; 178: 2655-60.
180. Kissner TL, Moisan L, Mann E, et al. A small molecule that mimics the BB-loop in the Toll interleukin-1 (IL-1) receptor domain of MyD88 attenuates staphylococcal enterotoxin B-induced pro-inflammatory cytokine production and toxicity in mice. J Biological Chem 2011; 286: 31385-96.
181. Matsunaga N, Tsuchimori N, Matsumoto T, Ii M. TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Mol Pharmacol 2011; 79: 34-41.
182. Yamada M, Ichikawa T, Ii M, et al. Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents: synthesis and biological activity of alkyl 6-(Nsubstituted sulfamoyl)cyclohex-1-ene-1-carboxylate. J medicinal chemistry 2005; 48: 7457-67.
183. Kawamoto T, Ii M, Kitazaki T, Iizawa Y, Kimura H. TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain. Eur J Pharmacol 2008; 584: 40-8.
184. Takashima K, Matsunaga N, Yoshimatsu M, et al. Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model. Br J Pharmacol 2009; 157: 1250-62.
185. Rice TW, Wheeler AP, Bernard GR, et al. A randomized, doubleblind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Critical care Med 2010; 38: 1685-94.
186. Brown V, Brown RA, Ozinsky A, Hesselberth JR, Fields S. Binding specificity of Toll-like receptor cytoplasmic domains. Eur J Immunol 2006; 36: 742-53.
187. Ogus AC, Yoldas B, Ozdemir T, et al. The Arg753GLn polymorphism of the human toll-like receptor 2 gene in tuberculosis disease. The European respiratory journal: official J Eur Soc Clin Respiratory Physiol 2004; 23: 219-23.
188. Ronni T, Agarwal V, Haykinson M, Haberland ME, Cheng G, Smale ST. Common interaction surfaces of the toll-like receptor 4 cytoplasmic domain stimulate multiple nuclear targets. Mol Cellular Biol 2003; 23: 2543-55.
189. Nagpal K, Plantinga TS, Wong J, et al. A TIR domain variant of MyD88 adapter-like (Mal)/TIRAP results in loss of MyD88 binding and reduced TLR2/TLR4 signaling. J Biological Chem 2009; 284: 25742-8.
190. Netea MG, Wijmenga C, O'Neill LA. Genetic variation in Toll-like receptors and disease susceptibility. Nature Immunol 2012; 13: 535-42.
191. Davis CN, Mann E, Behrens MM, et al. MyD88-dependent and-independent signaling by IL-1 in neurons probed by bifunctional Toll/IL-1 receptor domain/BB-loop mimetics. Proce Natl Acad Sc USA 2006; 103: 2953-8.
192. Zhu Y, Li T, Song J, et al. The TIR/BB-loop mimetic AS-1 prevents cardiac hypertrophy by inhibiting IL-1R-mediated MyD88-dependent signaling. Basic Res Cardiol 2011; 106: 787-99.
193. Sha T, Iizawa Y, Ii M. Combination of imipenem and TAK-242, a Toll-like receptor 4 signal transduction inhibitor, improves survival in a murine model of polymicrobial sepsis. Shock 2011; 35: 205-9.
194. Toshchakov V, Jones BW, Perera PY, et al. TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. Nature Immunol 2002; 3: 392-8.
195. Li C, Zienkiewicz J, Hawiger J. Interactive sites in the MyD88 Toll/interleukin (IL) 1 receptor domain responsible for coupling to the IL1beta signaling pathway. J Biological Chem 2005; 280: 26152-9.
196. Stack J, Bowie AG. Poxviral protein A46 antagonizes Toll-like receptor 4 signaling by targeting BB loop motifs in Toll-IL-1 receptor adaptor proteins to disrupt receptor:adaptor interactions. J Biological Chem 2012; 287: 22672-82.
197. Liu C, Swaidani S, Qian W, et al. A CC' loop decoy peptide blocks the interaction between Act1 and IL-17RA to attenuate IL-17-and IL-25-induced inflammation. Science signaling 2011; 4: ra72.
198. Snyder GA, Cirl C, Jiang J, et al. Molecular mechanisms for the subversion of MyD88 signaling by TcpC from virulent uropathogenic Escherichia coli. Proce Natl Acad Sci 2013; 110(17): 6985-90.
199. Radhakrishnan GK, Harms JS, Splitter GA. Modulation of microtubule dynamics by a TIR domain protein from the intracellular pathogen Brucella melitensis. Biochem J 2011; 439: 79-83.